BRCA2 and central nervous system cancer: All BRCA2 GVs identified here were LoF variants resulting in a reduced BRCA2 expression and an increased PARP1 expression, on average, in glioma sections compared to gliomas from non-BRCA2 GV carriers, thus impacting the molecular tumor phenotype.